Cancer Stem Cells

news May 01 2017

The Need of Certain Marker Panel to Identify CSCs Subpopulation

Even cancer therapy is more effective than it was a few years ago, it is still none treatments that can cure cancer effectively. The reason could be due to the subpopulation called “cancer stem cells” (CSCs), being defined as those cells within a tumor that have properties of stem cells: self-renewal and the ability for differentiation into multiple cell types that occur in tumors. 

Isolation of pure CSCs populations or reprogramming cancer cells into CSCs from cancer cell lines or primary tumors could be a great tool to gain an in-depth knowledge about heterogeneity and plasticity of CSC phenotype. For that reason, we need a certain marker panel that allows identifying CSCs subpopulation. Broad spectrum of cell surface stem cell markers e.g. CD44 (15675-1-AP), CD24 (18330-1-AP), CD1333 (18470-1-AP) or LC3B (18725-1-AP) since autophagy is also required for self-renewal and differentiation of adult human stem cells, allowed the identification of CSCs in human solid tumors, including brain, breast, prostate, pancreas, liver, ovary, skin and colon cancers, and melanoma.

LC3B-Specific Antibody staining (18725-1-AP; 1:50; green) with HepG2 cells. Cells werefixed with 4% PFA, permeabilized with 0.2% Triton X-100, and co-stained with Tubulin (66031-1-Ig; 1:100; red), under 40 x.